Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics reported positive interim results from a Phase 1/2 study of MRT-2359 plus enzalutamide in heavily pretreated metastatic castration-resistant prostate cancer. Among 20 patients enrolled, safety was favorable, with mainly mild or moderate gastrointestinal side effects.
Of 14 evaluable patients with non-neuroendocrine disease, 4 had androgen receptor mutations and all 4 achieved PSA responses, including 2 PSA90 responses. Two partial tumor responses were seen in this AR-mutant subset, giving a 100% disease control rate, while overall disease control among evaluable patients was 64% (9 of 14). Monte Rosa plans a Phase 2 study in up to 25 patients with AR-mutant disease anticipated to start in 2026 and expects to share updated MRT-2359 data at the ASCO Genitourinary Cancers Symposium in February.
The company also highlighted MRT-8102, a first-in-class NEK7-directed degrader for inflammatory diseases, with Phase 1 dosing underway in a cardiovascular risk cohort and interim data planned for early 2026.
Monte Rosa Therapeutics (GLUE) reported Q3 2025 results. Collaboration revenue was $12.8 million, up from $9.2 million a year ago. Operating expenses were $45.7 million, driven by R&D of $36.7 million and G&A of $9.1 million, resulting in a net loss of $27.1 million for the quarter.
Year to date, the company recorded net income of $7.5 million, reflecting recognition tied to collaboration activity, including completion of the $150.0 million upfront under the 2024 Novartis license. Cash, cash equivalents and marketable securities totaled $391.3 million as of September 30, 2025, with positive operating cash flow of $20.2 million for the nine-month period.
Deferred revenue was $136.7 million (current $24.8 million; noncurrent $111.9 million), supported by major partnerships. The Sept. 2025 Novartis agreement added a $120.0 million upfront (with up to $5.4 billion in potential milestones), of which $0.4 million has been recognized and $119.6 million deferred. Under the Roche collaboration, $44.9 million has been recognized to date with $17.1 million remaining deferred. Management expects existing liquidity to fund operations for at least 12 months.
Monte Rosa Therapeutics (GLUE) furnished an update on operations, announcing it has reported financial results for the quarter ended September 30, 2025. The full details are contained in a press release furnished as Exhibit 99.1.
The company also posted a revised corporate presentation to the Presentations section of its website on November 6, 2025. Information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liability or incorporated by reference unless expressly stated.
Monte Rosa Therapeutics, Inc. received a joint Schedule 13G filing showing that Dimension Capital I, L.P. and affiliated reporting persons collectively beneficially hold 4,757,563 shares of the issuer's common stock, representing 7.7% of the class. The filing lists the reporting persons as Dimension Management, L.P., Dimension Capital I GP, LLC, Dimension Management GP, LLC, Dimension Capital I, L.P. and individuals Adam Goulburn, Zavain Dar, and Nan Li. The cover information states the ownership percentages are calculated using 61,759,350 outstanding shares reported by the issuer as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the disclosed shares and certify the shares were not acquired to change control of the company.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,725,000 shares of Monte Rosa Therapeutics common stock, representing 6.1% of the class. The reporting persons state they have sole voting and sole dispositive power over these shares and that the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The percentage is calculated using 61,509,821 shares outstanding as of May 5, 2025, per the company's quarterly report. The filing includes a certification that the securities were acquired in the ordinary course of business and were not acquired to change or influence control; signatures appear for Avoro and for Behzad Aghazadeh.